Recombinant kringle 1-3 of plasminogen inhibits rabbit corneal angiogenesis induced by angiogenin.
OBJECTIVE
Angiostatin is a potent angiogenesis inhibitor that has been identified as a cryptic fragment of plasminogen molecule containing the first four kringle domain. Angiogenin, a 14-kDa monomeric protein, a potent blood vessel inducer, is expressed in tumors and present in mammalian plasma. The purpose of this study was to determine whether recombinant kringle 1-3 (rKI-3) of human plasminogen could interfere with angiogenesis induced by angiogenin and to evaluate the role of angiogenin in corneal angiogenesis in rabbit.


METHODS
A Hydron polymer pellet containing 2.0 microg of angiogenin was implanted intrastromally into the superior cornea of each of 44 rabbit eyes. All eyes received an intrastromal pellet and were randomized into either one group treated with 12.5 microg of rKI-3 (n = 25) or the other group treated with phosphate-buffered saline (PBS; n = 19). Both pellets were positioned in parallel at the site 1.2 mm from the superior limbus. Two masked observers kept the angiogenesis score daily, based on the number and the length of new vessels. The corneas with induced angiogenesis also were examined histologically.


RESULTS
On the third day of the angiogenin pellets implantation, the eye treated with rKI-3 had less angiogenesis (mean score, 4.2 +/- 6.6) than eye treated with PBS (mean score, 16.1 +/- 17.1; p < 0.05, Mann-Whitney U test). The cornea treated with PBS also showed much more leukocyte adhesion than the cornea treated with rKI-3.


CONCLUSIONS
Recombinant kringle 1-3 appears to inhibit angiogenin-induced angiogenesis in a rabbit corneal pocket assay. Recombinant kringle 1-3 may have therapeutic potential as an antiangiogenic agent.
Shin
S H
SH
Department of Ophthalmology, Yongsan Hospital, Chung Ang University Medical Center, Seoul, Korea.
Kim
J C
JC
Chang
S I
SI
Lee
H
H
Chung
S I
SI
D043925:Angiogenesis Inducing Agents / Q000633:toxicity*; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002448:Cell Adhesion / Q000187:drug effects; D003315:Cornea / Q000187:drug effects / Q000473:pathology*; D016510:Corneal Neovascularization / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D004195:Disease Models, Animal; D004343:Drug Implants; D007962:Leukocytes / Q000187:drug effects / Q000502:physiology; D008297:Male; D010446:Peptide Fragments / Q000008:administration & dosage*; D010958:Plasminogen / Q000008:administration & dosage*; D011817:Rabbits; D011897:Random Allocation; D011994:Recombinant Proteins; D012259:Ribonuclease, Pancreatic / Q000633:toxicity*
D043925:Angiogenesis Inducing Agents; D000970:Antineoplastic Agents; D004343:Drug Implants; D010446:Peptide Fragments; D011994:Recombinant Proteins; C402400:recombinant kringle 1-3 (rKI-3) of human plasminogen; D010958:Plasminogen; C046366:angiogenin; D012259:Ribonuclease, Pancreatic